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Abstract: The capacity of fibrinolytic enzymes to degrade blood clots makes them of high relevance in medicine
and in the pharmaceutical industry. In this work, forty-three microorganisms of the genus Bacillus were evaluated
for their potential to produce fibrinolytic proteases. Thirty bacteria were confirmed as producers of fibrinolytic
enzymes, the best results obtained for the strain Bacillus amyloliquefaciens UFPEDA 485. The optimization of the
enzyme production conditions was done by a central composite design (CCD) star 23 that allowed to define the opti-
mal conditions for soybean flour and glucose concentrations and agitation rate. The highest fibrinolytic activity (FA)
of 813 U mL-1 and a degradation of blood clot in vitro of 62% were obtained in a medium with 2% (w/v) of soybean
flour and 1% (w/v) glucose at 200 rpm after 48 h of cultivation, at pH 7.2 and 37 °C. The obtained fibrinolytic
enzyme was characterized biochemically. Fibrinolytic activity was inhibited by PMSF (fluoride methylphenylsulfo-
nyl - C7H7FO2S) 91.52% and EDTA (ethylenediaminetetraacetic acid - C10H16N2O8) 89.4%, confirming to be a ser-
ine-metallo protease. The optimum pH and temperature were 7.0 and 37 oC, respectively, and the enzyme was stable
for 12 h. The fibrinolytic activity at physiological conditions of this enzyme produced by Bacillus amyloliquefaciens
UFPEDA 485, as well as its long term stability, demonstrate that it has suitable characteristics for human and veter-
inary applications, and promises to be a powerful drug for the treatment of vascular diseases.
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Introduction
The genus Bacillus is considered one of the largest pro-
ducers of biotechnological molecules. The characterization
of the B. subtilis 168 genome and other species of the genus
facilitated their exploitation in industrial processes. Among
numerous advantages, Bacillus present short fermentation
cycles, and some species are considered safe in food and
drug administration.1,2 Research shows that the genus Bacil-
lus, has contributed to the development of new therapeutic
bioproducts: hydrogel,3 vaccine,4 antibiotic,5 biosurfactant,6
and fibrinolytic proteases.7,8
Proteases from microbial sources are hydrolytic enzymes
that play an important role in cell metabolism and have
attracted great interest from the pharmaceutical industry.
Although several proteolytic enzymes are being produced,
its production is not sufficient to meet the growing demand
in the world market.9 Among the several proteases, enzymes
with fibrinolytic activity have gained importance in the medi-
cal and pharmaceutical industry due to their effectiveness to
degrade blood clots in vitro and in vivo.10,11
Fibrin, a protein component of blood clots is responsible
for the occurence of thrombolytic disorders. The human body
produces various kinds of enzymes that assist the formation
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of thrombus, but only one enzyme, plasmin (EC 3.4.21.7),
may break and remove the clot, because it acts directly by
dissolving the blood clot and maintaining blood flow at sites
of vascular injury.12 
Fibrinolytic agents are commercially available for clinical
use and are plasminogen activators, such as urokinase and
streptokinase (bacterial origin). They present several disad-
vantages such as short half-life, high cost, need for high doses,
collateral effects, including allergic reactions and hemorrhagic
complications.13 On the other hand, plasmin and enzymes such
as nattokinase, lumbrokinase (EC 3.4.17.13) and fibrolase are
fibrinolytic enzymes which directly degrade fibrin thrombus
dissolving blood clots quickly and completely. Thus, enzymes
with such properties are required as alternatives for a supe-
rior therapy in the treatment of cardiovascular diseases and
a continued research for new fibrinolytic agents is needed.14
Fibrinolytic enzymes were discovered in insects,15 snake
venom,16 fruits such as Campomanesia xanthocarpa, popularly
known as “guavirova”,17 brown algae,18 fermented foods Bacil-
lus subtilis natto19 and are produced by various microorgan-
isms, mainly bacteria of the genus Bacillus, widely studied due
to their potential to produce potent fibrinolytic proteases.20-22
The definition of the time required for the enzymes to be
produced by microorganisms demands the use of methods
that can accelerate the production process and the effect of
the main process variables. Among others, central compos-
ite design (CCD) and response surface methodology (RSM)
are statistical tools widely used in the optimization of fer-
mentation processes involving enzyme production.23 
Thus, considering the biotechnological potential of Bacil-
lus strains for the production of bioactive compounds, this
work presents results on the screening, production and bio-
chemical characterization of a fibrinolytic protease produced
by Bacillus spp. as well as the in vitro evaluation of its ther-
apeutic potential.
Experimental
Screening and Culture Conditions. Forty-three Bacillus
sp. were obtained from Cultures Collections of Department
of Antibiotics (Federal University of Pernambuco) and Catho-
lic University of Pernambuco, Brazil. The stock culture was
stored in 10% v/v glycerol solution at -80 oC. Stock culture
was inoculated in nutrient broth at 37 oC, 150 rpm. After 24 h
of growth, the inoculum was standardized for an optical
density of 0.1 at 600 nm using a spectrophotometer (Ultro-
spec 9000, GE Healthcare Life Sciences, Cambridge, UK)
and the screening experiments done. 
Soybean medium (MS-2)24 was used for the production of
fibrinolytic proteases. The medium is composed by: filtered
soybean flour (2% w/v), K2HPO4 (0.435% w/v), NH4Cl
(0.1% w/v), MgSO4·7H2O (0.06% w/v), glucose (1% w/v)
and 1% of mineral solution (v/v) containing: FeSO4·7H2O
(100 mg); MnCl2·4H2O (100 mg), and ZnSO4·H2O (100 mg)
in 100 mL of distilled water. The production was done in
shaken flasks of 250 mL with 100 mL of culture medium, pH
7.2, for 48 h, at 150 rpm and 37 oC. At the end of the production
process, the culture medium was centrifuged at 10,000 g for
10 min to obtain the enzyme extract. 
Microbial Identification. Microbial identification was done
using 16S and rpoB genes and the sequencing was performed
by STAB VIDA in Lisbon, Portugal. A sequence similarity
search was performed in the National Center for Biotechnol-
ogy (NCBI) database using Basic Local Alignment Search Tool
(BLAST) (http://www.ncbi.nih.gov/BLAST/). For 16S rRNA
(ribosomal ribonucleic acid) sequencing, total genomic DNA
(deoxyribonucleic acid) was extracted from the nutrient broth.
The partial sequence of the 16S rRNA gene was amplified
using a polymerase chain reaction (PCR) and bacterial uni-
versal primers specific to 16S rRNA gene. For further char-
acterization of the microorganism the rpoB gene fragment
which encodes the β subunit of RNA polymerase was inves-
tigated. The rpoB gene fragment was amplified from the genome
DNA of B. amyloliquefaciens and B. subtilis by PCR using
the following primers 5'-ATC GAA ACG CCT GAA GGT
CCA AAC AT-3' and 5'-ACA CCC TTG TTA CCG TGA CGA
CC-3'. The data base used was the Blast NCBI, and sequence
comparison program used was Chromas Lite.
Central Composite Design (CCD) and Response Surface
Methodology (RSM). The CCD using two levels and three
factors was composed of 17 runs with 3 repetitions at the cen-
tral point, needed to calculate the pure error. The goodness of
fit was evaluated by the adjusted coefficient of determina-
tion (R2 adj) and the analysis of variance (ANOVA), as well as
comparative analysis by the plot of the predicted values with
the observed experimental values. The independent variables
were soybean flour concentration (1.0, 2.0, and 3.0% w/v);
glucose concentration (0.5, 1.0, and 1.5% w/v) and agitation
rate (100, 150, and 200 rpm) and fibrinolytic activity (U mL-1)
was the response variable.
Statistical significance of the variables was determined at
5% probability level (p<0.05). The analysis of the results
was carried with the program Statistic version 8.0. RSM using
CCD was employed to optimize the selected three variables
by the second order polynomial Eq. (1):
(1)
where Y is the response (fibrinolytic activity); xi and xj rep-
resent the independent variables; b0, bi, bii, bij, were the coef-
ficients of linear terms, square terms, and coefficients of
interactive terms, respectively.
Determination of Total Protein. Total protein concentra-
tion was determined by the Bradford method using as stan-
dard bovine serum albumin (BSA).25
Degradation of Blood Clots. The used blood was extracted
from the jugular of healthy young horses. The required vol-
ume of blood for clot formation was standardized and added
Y b0 bi xi bii xii2 bij xixj+ + +=
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without anticoagulant in test tubes having its walls previ-
ously wetted with saline solution. After blood clotting, the
tubes were placed in water bath at 37 oC for 1 h to separate
the serum from the clot of fibrin. The retracted clots were
washed with saline solution up to the obtention of a translucent
solution. Then, the clots were transferred to test tubes with
enzyme extract and kept at rest for 1 h at 37 oC. The sizes of
the clots were standardized to 50% (w/v) in relation to the volume
of enzyme extract. A saline solution was used as a negative
control. The percentage of degradation of the clot (PDC) was
calculated according to Eq. (2), where weight0 (zero) is the
weight of the clot formed spontaneously before the treat-
ment with the enzyme extract. The weightr is the weight of
the residue remaining after treatment with the enzyme extract.26
(2)
Fibrinolytic Activity Determination by Fibrin Plate.
The fibrin plate method27 was used to evaluate the fibrino-
lytic activity in the screening process. The fibrin plate contained
4 mL of 2 mg mL-1 fibrinogen solution (Fibrinogen from
bovine plasma in Tris-HCl 150 mM containing NaCl 150 mM
pH 7.7), 200 µL solution of thrombin from bovine plasma
(20 U mL-1 diluted in saline); 4 mL of agarose solution (2%)
and 100 mL of CaCl2 solution (1 M). The reaction mixture was
placed in plastic Petri dishes. After fibrin polymerization, 5 mm
diameter holes were made, where 20 µL of enzymatic extract
were placed. Then the plates were incubated at 37 oC for 18 h
and the diameter of the halos measured. Assays for the stan-
dard curve were performed in triplicate and the values of the
diameters of the halos were obtained by average of the repeti-
tions. One unit (U) of fibrinolytic activity corresponds to the
correlation between the diameter of the degradation halos in
fibrin plate (mm) and the standard curve made using plasmin
from human plasma. The activity was expressed in U·mL-1.
Fibrinolytic Activity (FA) Determination by Spectrometry.
The fibrinolytic activity28 of the enzyme extract obtained after
the optimization experiments was measured as follows: a
reaction mixture containing 0.1 mL of 245 mM phosphate
buffer (pH 7.0) and 0.4 mL of 0.72% fibrinogen solution was
incubated at 37 oC for 5 min; then, 0.1 mL of a 20 U·mL-1
thrombin solution was added and the reaction mixture was
again incubated at 37 oC for 10 min. After clot formation,
0.1 mL of diluted enzyme solution was added, and incubation
continued at 37 oC for 60 min, the reaction mixture being shaken
every 20 min. The reaction was stopped by adding 0.7 mL
of 0.2 M trichloroacetic acid (TCA). The reaction mixture
was centrifuged at 15000 g for 10 min, and the absorbance
of the supernatant was measured at 275 nm by spectropho-
tometry. In this assay, one unit of fibrinolytic protease activity
was defined as the amount of enzyme required to produce
an increase in absorbance equal to 0.01 per minute, equiva-
lent to the release of tyrosine. All experiments were per-
formed in triplicate.
Determination of Optimum pH and Temperature of the
Enzyme. Optimum pH and temperature of the fibrinolytic
enzyme activity was determinated. The optimum pH was
determinated at 37 oC at pH values between 3.0 and 10.0.
The buffers used were Glycine-HCl (pH 3.0), Sodium acetate
(pH 4.0-5.0), Citrate phosphate (pH 6.0), Tris-HCl (pH 7.0-8.0),
Glycine-NaOH (pH 9.0-10.0). The concentration of the buf-
fers was standardized at 20 mM. The optimum temperature
was determinate at pH 7.0 and the range of values was from
4 to 80 oC.
Effect of pH and Temperature on the Stability of the
Enzyme. The effect of pH and temperature on enzyme stability
was evaluated for 12 h; aliquots were removed at intervals
of 2 h to determinate the residual enzyme activities.
Effect of Metal Ions and Protease Inhibitors on Fibrino-
lytic Activity. The inhibitors and metal ions were dissolved
in 150 mM Tris-HCl buffer (NaCl 150 mM pH 7.75); the
concentration of the solutions was standardized at 5 mM. The
enzyme extract was incubated for 1 h at 37 oC. The inhibi-
tors investigated were PMSF (fluoride methylphenylsulfonyl),
EDTA (ethylenediaminetetraacetic acid), β-mercaptoethanol
(2-hydroxy-1-ethanethiol - C2H6SO), Pepstatin A (4-amino-
3-hidroxy-6-methyl-heptanoic - C34H68N5O9). The metal ions
evaluated were FeSO4, CuSO4, CaCl2, MgSO4, CoCl2, ZnSO4,
KCl, and MgCl2.
Results and Discussion
Screening of Fibrinolytic Enzyme Producer. Forty-three
strains of Bacillus were evaluated, among which thirty (70%)
exhibited fibrinolytic activity (Table I). These results show
the potential of the genus Bacillus as a producer of fibrino-
lytic enzymes. Other researchers29 isolated microorganisms
from the Chinese soybean cheese doufuru as well as Japanese
natto and Chinese douche and, among the isolates obtained,
sixteen microorganisms showed fibrinolytic activity, the highest
value of 1833 U mL-1 obtained by Bacillus subtilis. In another
work,30 Bacillus sp. strain AS-S20-I was the best producer of
fibrinolytic proteases with a maximum activity of 145.8 U mL-1 .
This value was lower than the one obtained by Bacillus sp.
UFPEDA 485, the highest producer in this work, that pre-
sented a fibrin degradation halo with 29 mm diameter (Fig-
ure 1), corresponding to a fibrinolytic activity of 720 U mL-1.
Bacteria Identification Using 16S and rpoB Genes. The
identification based on 16S rRNA gene sequence analysis showed
99% similarity homologies with the species Bacillus amylo-
liquefaciens and Bacillus subtilis. To differentiate between
these two Bacillus genus, rpoB region analysis was carried
out which showed higher identity to Bacillus amyloliquefaciens
species. The Blast from the consensus sequence revealed about
98% homology with the region DNA-directed RNA polymerase
β-subunit of the species Bacillus amyloliquefaciens and 89%
homology to the same region of the Bacillus subtilis species.
Identification by the rpoB region sequencing analysis offered
PDC Weight0 Weightr–Weight0
---------------------------------------------   100=
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advantages over the 16S because the rpoB gene has a higher
degree of polymorphism compared to 16S, making it more
accurate for species identification. The heterogeneity of the
16S rRNA gene hampers the quantification of bacterial species
by PCR based assays. In contrast, the rpoB gene is common
to all bacteria and occurs as a single copy in the genome. This
also was observed by Ki31 that identified thirteen different
Bacillus species by 16S and rpoB genes and observed levels
of similarity of 90.3% to B. hwajinpoensis and B. sporother-
modurans and 99.8% to B. anthracis and B. cereus.
In this work, analysis of 16S and rpoB region confirmed
that the sample tested has a higher homology to the Bacillus
amyloliquefaciens and demonstrate that the polymorphism
of the Bacillus rpoB gene can be used to identify Bacillus
species, providing improvement over conventional methods
in the identification of Bacillus species. The result was sub-
mitted to the GenBank database.
Optimization of the Conditions for Fibrinolytic Enzyme
Production from Bacillus Amyloliquefaciens UFPEDA 485.
The optimization of the conditions for the production of the
Figure 1. Halo fibrin degradation of the fibrinolytic enzyme of
Bacillus sp. UFPEDA 485 after 48 h incubation (A), positive control
with plasmin (B), and negative control with physiological solu-
tion (C).
Table I. Microorganisms of the Genus Bacillus and Their Fibrinolytic Activity after 48 h of Cultivation in Soybean Medium
(MS-2), pH 7.2, 150 rpm, and 37 oC
Microorganisms FA (U mL-1) a Microorganisms FA (U mL-1) a
B. subtilis UCP 999 -b B. circulans UFPEDA 436 267 ± 0.83
B. licheniformis UCP 1008 342 ± 1.01 Bacillus sp. UFPEDA 437 22.5 ± 0.93
B. licheniformis UCP 1009 1.1 ± 0.02 Bacillus sp. UFPEDA 449 342 ± 1.61
B. licheniformis UCP 1010 -b Bacillus sp. UFPEDA 450 99.3 ± 0.54
B. licheniformis UCP 1013 60.6 ± 1.07 Bacillus sp. UFPEDA 451 -b
B. licheniformis UCP 1016 163 ± 0.92 B. cereus UFPEDA 452 -b
B. licheniformis UCP 1033 163 ± 0.82 B. alvei UFPEDA 461 99.3 ± 1.33
B. licheniformis UCP 1477 163 ± 0.82 Bacillus sp. UFPEDA 464 163 ± 0.73
B. licheniformis UCP 1482 99.3 ± 0.89 Bacillus sp. UFPEDA 465 36.9 ± 0.10
B. cereus UFPEDA 11 -b Bacillus sp. UFPEDA 466 -b
Bacillus. sp. UFPEDA 12 -b Bacillus sp. UFPEDA 469 267 ± 0.00
Bacillus. sp. UFPEDA 13 13.7 ± 0.74 B. licheniformis UFPEDA 470 -b
B. mycoides UFPEDA 14 8.4 ± 0.08 B. firmus UFPEDA 471 -b
B. subtilis UFPEDA 15 -b B. pumilus UFPEDA 472 209 ± 1.49
B. subtilis UFPEDA 16 -b B. pumilus UFPEDA 474 60.6 ± 1.46
B. subtilis UFPEDA 86 8.4 ± 0.09 Bacillus sp. UFPEDA 483 267 ± 0.08
B. megaterium UFPEDA 108 3.1 ± 0.09 Bacillus sp. UFPEDA 484 -b
B. subtilis v. aterrimus UFPEDA 170 0.51 ± 0.08 Bacillus sp. UFPEDA 485 720 ± 0.08
Bacillus. sp. UFPEDA 189 267 ± 1.51 Bacillus sp. UFPEDA 486 4.0 ± 0.08
Bacillus. sp. UFPEDA 194 47.3 ± 0.74 Bacillus sp.UFPEDA 487 -b
B. subtilis UFPEDA 260 5.1 ± 0.10 Bacillus sp.UFPEDA 488 1.5 ± 0.03
B. subtilis UFPEDA 404 209 ± 1.03
aFA - Fibrinolytic activity by fibrin plate method and correlated with a standard curve of plasmin. bAbsence of FA (-).
Fibrinolytic Potential from New Bacillus Amyloliquefaciens
Macromol. Res., Vol. 24, No. 7, 2016 591
fibrinolytic enzyme from Bacillus amyloliquefaciens UFPEDA
485 was conducted according to a CCD star 23 with two levels
and three factors and the response variable was fibrinolytic
activity (FA) after 48 h of cultivation (Table II).
The increase of the concentration of the independent vari-
ables - soybean flour and glucose and its interaction had a
linear effect positive and statistically significant on the
increase of the fibrinolytic activity. For the quadratic effect,
the increase of the concentration of the independent vari-
ables soybean flour, glucose and its interaction was statisti-
cally significant and had a negative effect on the increase of
the fibrinolytic activity. The results from the analysis of
variances and effect estimates for the main factors are shown
in Table III. The variation around the mean of the residuals
is fully explained by pure error, because there is no evidence
of lack of fit, and a good model fit is obtained. The p value
for lack of fit was < 0.00. The validity of the model is con-
firmed by the ANOVA analysis.
The quality of the model can be confirmed by the proximity
of the data with the straight line shown in Figure 2. The dis-
tribution of the data points along the diagonal line indicates
the good fit of the model.
Using the obtained values in presented the Table II, the corre-
sponding multiple regression equation was calculated. The
quadratic effect of the variable (X3) was ignored in Eq. (3)
as its effect was not statistically significant. 
From the regression analysis, Eq. (3) was obtained:
Y = – 151 + 178 X1 – 51.3 X12 + 506 X2 – 282 X22 + 2.93 X3
   + 45 X1·X2 – 0.14 X1·X3 – 0.17 X2·X3 (3)
The optimum conditions for the production of FA were
1.88% (w/v) of soybean flour and 0.988% (w/v) of glucose
at 200 rpm. Under these conditions the calculated value was
Table II. Matrix of the Central Composite Design (CCD) Star for the Optimization of the Conditions for Production of the
Fibrinolytic Enzyme from Bacillus Amyloliquefaciens UFPEDA 485
Runs Soybean Flour (%) Glucose (%) Agitation (rpm) Fibrinolytic Activity (U mL-1)
1 1.0 ( - ) 0.5 ( - ) 100 ( - ) 462 ± 0.014
2 1.0 ( - ) 1.5 ( + ) 200 ( + ) 682 ± 0.003
3 3.0 ( + ) 0.5 ( - ) 200 ( + ) 666 ± 0.013
4 3.0 ( + ) 1.5 ( + ) 100 ( - ) 492 ± 0.004
5 (C) 2.0 ( 0 ) 1.0 ( 0 ) 150 ( 0 ) 702 ± 0.006
6 1.0 ( - ) 0.5 ( - ) 200 ( + ) 710 ± 0.008
7 1.0 ( - ) 1.5 ( + ) 100 ( - ) 419 ± 0.005
8 3.0 ( + ) 0.5 ( - ) 100 ( - ) 413 ± 0.009
9 3.0 ( + ) 1.5 ( + ) 200 ( + ) 696 ± 0.011
10 (C) 2.0 ( 0 ) 1.0 ( 0 ) 150 ( 0 ) 701 ± 0.003
11 1.0 ( - ) 1.0 ( 0 ) 150 ( 0 ) 636 ± 0.004
12 3.0 ( + ) 1.0 ( 0 ) 150 ( 0 ) 613 ± 0.004
13 2.0 ( 0 ) 0.5 ( - ) 150 ( 0 ) 607 ± 0.026
14 2.0 ( 0 ) 1.5 ( + ) 150 ( 0 ) 604 ± 0.007
15 2.0 ( 0 ) 1.0 ( 0 ) 100 ( - ) 538 ± 0.006
16 2.0 ( 0 ) 1.0 ( 0 ) 200 ( + ) 813 ± 0.014
17 (C) 2.0 ( 0 ) 1.0 ( 0 ) 150 ( 0 ) 701 ± 0.004
Table III. Analysis of Variance (ANOVA) for the Response
Fibrinolytic Activity, Over the Independent Variables Soybean
Flour (%), Glucose (%) and Agitaton (rpm), According to CCD
Star, with 95% Confidence Level
Factor
Fibrinolytic Activity
Estimates Effect p Value
(1) Soybean flour (%) (L) 178 0.00
Soybean flour (%) (Q) -51.3 0.00
(2) Glucose (%) (L) 506 0.00
Glucose (%) (Q) -282 0.00
(3) Agitation (rpm) (L) 2.93 0.00
1L by 2L 45.0 0.00
1L by 3L -0.14 0.00
2L by 3L -0.17 0.00
Regression Coefficient ANOVA
Pure Error = 0.18 R2 = 0.99 R2adjusted  = 0.97
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808 U mL-1, very close to the value of 813 U mL-1, observed
when the FA was calculated for the experimental conditions -
soybean flour (2%), glucose (1%), and agitation (200 rpm).
This makes irrelevant to adjust the optimum conditions from
1.88% to 2% in soybean flour concentration and of 0.99%
to 1% in glucose concentration.
Response surface plot showing the effect of the independent
variables soyben flour (% w/v) and glucose (% w/v) con-
centration with agitation at 200 rpm, after 48 h of cultiva-
tion on the response variable fibrinolytic activity of Bacillus
amyloliquefaciens UFPEDA 485 is displayed in Figure 3. 
Previous researches have proved that glucose is a preferred
carbon source for the growth of Bacillus spp. Other carbon
sources such as fructose, maltose, lactose, sucrose and glycerol
have shown minimum solubility, poor cellular uptake and
unsuitable metabolic pathway reducing the production of fibri-
nolytic enzymes.14 An optimum glucose concentration of
1.25% w/v for maximum fibrinolytic activity from Bacillus
sphaericus MTCC 367214 was reported, a result similar to
the value obtained in this work. 
Other researchers optimized the production of fibrinolytic
enzyme by Plackett-Burman Design, using soybean as a nitro-
gen source. In this case, maximum activity obtained in sub-
merged fermentation was 797.28 U mL-1 at 72 hours, using
soybean meal at a concentration of 1.5% (w/v).32 In another
study, the optimum conditions at laboratory scale for the maxi-
mal production of the fibrinolytic enzyme were obtained at
pH 7.2, temperature 37 ºC and agitation 200 rpm, for a max-
imal activity of 28.98 U mL-1 at 72 h.33 Unlike this study, using
a central composite design (star) 23 in shake flasks that achieved
the best result for fibrinolytic activity using soybean flour
(2% w/v) and glucose (1% w/v) in 48 h and showed better
performance in production process.
Evaluation of Fibrinolytic Activity by Degradation Of
Blood Clots. The enzyme extract produced by Bacillus amylo-
liquefaciens UFPEDA 485 showed a high effectiveness in
degrading blood clots in vitro. After 1 h, the results showed
a PDC of 62% while the negative control containing saline
solution kept the clot intact (Figure 4). The degradation of blood
clots goat after 24 h using crude extract from the Paeniba-
cillus sp. IND834 was also evaluated and a complete degra-
dation of the human blood clot after 18 h using the enzyme
from Bacillus sp. SFN35 was observed. Fibrinolytic protease
from Fusarium sp. was able to degrade 36.5% of mouse blood
clots at room temperature for 1 h.26 The potencial of the enzyme
from Fusarium sp. to degrade blood clots is much lower when
compared with the fibrinolytic enzyme from Bacillus amy-
loliquefaciens UFPEDA 485 produced in this work, that shows
a two times higher capacity for the degradation of blood clots
within 1 h.
Effects of pH and Temperature on the Activity and Stability
of the Enzyme. The enzyme showed higher values  of fibri-
nolytic activity at neutral pH, with an optimum at pH 7.0
(Figure 5(a)). After incubation for 12 h, the enzyme retained
Figure 2. Relationship between the experimental values and the
predicted values by the model for fibrinolytic activity (FA), accord-
ing to central composite design (CCD) star.
Figure 3. Response surface plot showing the effect of indepen-
dent variables: soyben flour (%) and glucose (%) with agitation
at 200 rpm, after 48 h of cultivation on the response variable
fibrinolytic activity of Bacillus amyloliquefaciens UFPEDA 485.
Figure 4. Degradation of blood clots by dispersion of red blood
cells. (a) Blood clots after 1 h in the enzyme extract from Bacil-
lus amyloliquefaciens UFPEDA 485 (in triplicate), (b) blood clot
after 1 h in physiological solution.
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82.89% of its activity at pH 7.0, 66.03% at pH 8.0, and 50%
at pH 6.0 and 9.0 after 8 h of incubation (Figure 5(b)).
Results corroborate with other researchers,12 that studied a
fibrinolytic enzyme produced by Bacillus licheniformis B4 -
an optimum pH of 7.5 was observed with the enzyme retained
100% of its activity at pH 7.0 after 30 min of incubation.
Fibrinolytic protease from Bacillus cereus NS-2 had an opti-
mum pH of 9.0 and its activity was lost in just 30 min.22 The
fibrinolytic enzyme produced by Bacillus amyloliquefaciens
UFPEDA 485 is very stable in physiological conditions, unlike
other fibrinolytic enzymes produced by other species of the
genus Bacillus.
The optimum temperature of the obtained fibrinolytic enzyme
was 37 oC (Figure 6(a)). After 12 h of incubation, the enzyme
remained stable at 4, 25 and 37 oC, maintaining activities of
96.04, 95.88, and 98.26%, respectively, and still maintained
58.84% of its activity at 40 oC (Figure 6(b)). Juamily and
Al-Zaidy12 related that fibrinolytic enzyme from Bacillus lichni-
formis B4 has an optimum temperature of 37 oC and retained
its total activity after 1 h of incubation when maintained at
20-40 oC; then the activity decreased with the increase of
temperature. in other study,22 an optimum temperature of 40 oC
and the enzyme lost 40-60% of its activity at each temperature
of incubation. These results confirm that the fibrinolytic enzyme
produced by Bacillus amyloliquefaciens UFPEDA 485 has
an excellent stability at the physiological temperature of the
blood, different from enzymes produced by others Bacillus
strains cited in the literature.
Figure 5. (a) Effect of pH on the fibrinolytic activity relative of the enzyme from Bacillus amyloliquefaciens UFPEDA 485 after 1 h of
incubation. (b) Effect of pH on the stability of enzyme measured at intervals of 2 h per 12 h of incubation of the enzyme and expressed
as percentage of residual activity. Buffers used: Glycine-HCl (pH 3.0), Sodium acetate (pH 4.0-5.0), Citrate phosphate (pH 6.0), Tris-
HCl (pH 7.0-8.0), Glycine-NaOH (pH 9.0-10.0). All buffer concentrations were 20 mM. Each value is the average of the results of three
experiments, and the error bars show the standard deviations.
Figure 6. (a) Effect of temperature on the fibrinolytic activity relative of the enzyme from Bacillus amyloliquefaciens UFPEDA 485
after 1 h of incubation. (b) Effect of temperature on the stability of enzyme measured at intervals of 2 h per 12 h of incubation of the
enzyme and expressed as percentage of residual activity. Each value is the average of the results of three experiments, and the error bars
show the standard deviations.
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Activity. The fibrinolytic activity was almost completely
inhibited after 60 min of incubation with PMSF (8.48%) and
EDTA (10.4%) in Table IV. The results show that the enzy-
matic extract from Bacillus amyloliquefaciens UFPEDA 485
contains serine-metallo proteases, indicating that the hydroxyl
(serine) group is located at or near the active site of one of
the enzymes contained in the extract, hence being inhibited
by PMSF (serine protease inhibitor); moreover, divalent metals
seem to be required for the enzyme to maintain its activity,
as an inhibition by chelating agents such as EDTA (metallo
protease inhibitor) occurs. Enzyme activity was less inhibited
by Pepstatin A (48.2%), an aspartic protease inhibitor and
β-mercaptoethanol (36.2%), a cysteine protease inhibitor.
Enzyme activity was significantly inhibited by FeSO4 (6.82%)
and slightly increased by CaCl2 (110%) (Table V). Both the
activation as the inhibition of the enzyme activity occurs due to
allosteric effects. The connection of a chemical substance with
the allosteric site of an enzyme may induce conformational
changes in the spatial structure of the enzyme, changing the
affinity by its substrate.
The influence of protease inhibitors in fibrinolytic enzyme
activity was also reported by other authors36 that observed a
significant inhibition in the presence of PMSF and EDTA;
in these situations the enzyme activity was 0% and 3.35%,
respectively. The enzyme was also classified as a serine-metallo
protease and similar results to those reported in this work
were obtained concerning the effect of metal ions as the enzyme
when incubated with CaCl2, increased slightly its fibrinolytic
activity to 118.15%.
The influence of protease inhibitors was also evaluated37
and unlike this work, the enzyme when incubated with PMSF
and EDTA, showed an activity of 2% and 92%, respectively,
being considered a serine protease. For the effect of metal ions
similar results to those reported in this work were obtained
as the enzyme activity slightly increased (to 111%) in the pres-
ence of CaCl2 and was reduced to 41% and 0%, respectively,
when incubated with CoCl4 and FeSO4.
Conclusions
From the 43 strains evaluated, Bacillus amyloliquefaciens
UFPEDA 485 was selected as the one producing the highest
fibrinolytic activity. The optimized culture medium for the
production of the fibrinolytic enzyme from Bacillus amylo-
liquefaciens UFPEDA 485 contained 1.88% (w/v) of soybean
flour and 0.99% (w/v) of glucose. The fibrinolytic protease
from Bacillus amyloliquefaciens UFPEDA 485 was shown
to have biochemical characteristics suitable for human and
veterinary applications, namely the best activity at physiological
conditions as well as the high thermal stability. These char-
acteristics differ from fibrinolytic enzymes produced by other
microorganisms described in the literature up to date. These
results demonstrate the biotechnological potential of Bacil-
lus amyloliquefaciens UFPEDA 485 for the production of a
protease suitable for the pharmaceutical industry and its
possible application on the treatment of vascular disorders.
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